Skip to main content

Can buy LIC Housing Finance, Delta Corp and SBI Life for short term

On the technical front, 12,750 and 29,500 would act as an immediate hurdle for Nifty and Bank Nifty, respectively.

Indian markets closed at record high on November 10 on the back of strong global cues.



So far, Nifty has surged more than 8 percent this month while Bank Nifty has gained nearly 19 percent as uncertainty over the US elections ended along with development in the COVID vaccine.

Banking and financial stocks surged sharply with Bajaj and HDFC twins among top gainers.

On the derivatives front, the rally was supported by short-covering, done by call writers at 12,400 and 12,500 strikes.

Furthermore, put writers added hefty open interest at 12,400 strikes and seen shifting at higher bands.

On the technical front, 12,750 and 29,500 would act as an immediate hurdle for Nifty and Bank Nifty, respectively.

However, secondary oscillators suggest that the market is a bit overheated now and traders should expect volatility in the coming sessions.

On the downside, 12,400 would act as strong support for Nifty with bias likely to remain in favour of bulls.

We advise traders to use any dip to create fresh longs. For Bank Nifty, the 28,000-27,500 zone is a strong support area.

Here are three buy calls for the next 2-3 weeks:

LIC Housing Finance | LTP: Rs 323.50 | Target price: Rs 353 | Stop loss: Rs 293 | Upside: 9%

For the last nearly ten weeks, the stock has been consolidating in a broader range of Rs 280-320 along with consistent buying around support levels.

On the daily charts, the stock is holding well above its short and long-term moving averages.

This week, the stock has managed to give a price volume breakout above its 200-days exponential moving average on the daily charts and also succeeded to close above the key resistance level of Rs 320 after a prolonged consolidation.

Delta Corp | LTP: Rs 119.50 | Target price: Rs 132 | Stop loss: Rs 108 | Upside: 10%

The stock has given a sharp rally from Rs 85 to Rs 115 in August 2020 and after that, it went into consolidation as prices were seen fluctuating in the range of Rs 100 to Rs 120 levels.

This week, the stock has managed to give consolidation breakout above the 200-day exponential moving average on a daily timeframe and also managed to close above it.

The positive divergences on secondary oscillators suggest further up-move in the prices as the breakout is well supported by additionally higher volumes.

SBI Life Insurance Company | LTP: Rs 831 | Target price: Rs 902 | Stop loss: Rs 775 | Upside: 9%

For the last three months, the stock has been consistently moving lower in a downward sloping channel with the formation of the lower high and lower bottom patterns.

However, this week the stock has once again moved back above its short-term moving averages with a breakout above the falling trend line of the sloping channel.

The breakout can be seen with rising volumes and positive divergences on secondary oscillators.

Disclaimer: Consult your financial advisor before any investments

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more